DAWN Q4 2021 Earnings — Day One Biopharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

DAWNDay One Biopharmaceuticals, Inc.

$2B

Q4 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

-$51,000

Operating Income

-$22M

Net Income

-$22M

EPS (Diluted)

$-1.93

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$13M

Free Cash Flow

-$5M

Stock-Based Comp.

$5M

Balance Sheet

Total Assets

$290M

Total Liabilities

$9M

Stockholders' Equity

$281M

Cash & Equivalents

$284M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	-$51,000	$0	—
Operating Income	-$22M	-$6M	-257.7%
Net Income	-$22M	-$34M	+36.2%